Cover Image
市場調查報告書

全球生物科技產業分析 (2015年):預測、成長機會、趨勢、課題

Analyzing the Global Biotechnology Industry 2015 (Global Biotechology Industry: Forecast, Growth Opportunities, Trends & Challenges)

出版商 Aruvian's R'search 商品編碼 337453
出版日期 內容資訊 英文 425 Pages
訂單完成後即時交付
價格
Back to Top
全球生物科技產業分析 (2015年):預測、成長機會、趨勢、課題 Analyzing the Global Biotechnology Industry 2015 (Global Biotechology Industry: Forecast, Growth Opportunities, Trends & Challenges)
出版日期: 2015年08月01日 內容資訊: 英文 425 Pages
簡介

從2008年到2009年的景氣低迷後,全球生物科技產業除了2013年的一時減速,以大幅度的成長率發展,今後直到2019年預計持續強力成長。中國和巴西、印度等新興市場領導銷售額。各地區的佔有率上南北美洲及歐洲各約45%、30%而佔大半,各用途上醫療及醫療保健部門約佔60% (2014年)是最大的終端用戶,其次依序為食品、農業。

本報告提供全球生物科技產業的發展趨勢的相關調查、產業定義、各種統計資料、資金籌措、投資等趨勢、市場及技術相關的主要趨勢與課題、主要國家的詳細分析、主要企業簡介等總括性彙整。

摘要整理

產業定義

全球生物科技產業

  • 產業統計
  • 產業的規模分析
  • 產業區分
    • 生物資訊學
    • 基因學
    • 醫藥基因學
    • 蛋白質體學
  • 資金籌措、投資
  • 全球生物科技產業:預測

全球生物科技產業:波特的五力分析組成架構分析

生物科技&醫藥品企業間界線的模糊化

全球生物科技產業:市場趨勢、課題

  • 簡介
  • 生物資訊學
  • 生物感應器技術
  • 細胞培養技術
  • 基因複製技術
    • 分子基因複製
    • 細胞基因複製
    • 動物基因複製
  • DNA晶片技術
  • 微陣列
    • DNA微陣列
    • 蛋白質微陣列
    • 組織微陣列
    • 全細胞微陣列
  • 單株抗體技術
  • 奈米生物科技
  • 組調換DNA技術
  • 產業的全球化
  • 生產率提高的課題
  • 對原料、能源來源的可獲取性與可用性
  • 個人化醫療的崛起
  • 生技仿製藥帶來的課題
  • 成本效率高的製造
  • 投資者的自信缺乏
  • 法律規章上的課題
  • 智慧財產權上的課題、專利
  • 財政的障礙
  • 新興市場上課題
  • 遺傳基因操作相關課題
  • 課題概要
  • 公共支援的不足

全球生物科技產業:主要市場分析

  • 比利時
  • 加拿大
  • 中國
  • 法國
  • 德國
  • 義大利
  • 日本
  • 荷蘭
  • 西班牙
  • 英國
  • 美國
  • 其他
    • 澳洲
    • 巴西
    • 古巴
    • 馬來西亞
    • 紐西蘭
    • 巴基斯坦
    • 羅馬尼亞
    • 新加坡
    • 韓國
    • 斯里蘭卡
    • 瑞士
    • 坦尚尼亞

全球生物科技產業:主要企業

  • Abbott Laboratories
  • Acorda Therapeutics Inc.
  • Actelion Ltd
  • Amgen, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Baxter International Inc.
  • Biogen Inc.
  • bioMerieux SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Crucell N.V.
  • 第一三共
  • F. Hoffmann-La Roche AG
  • Gentium S.p.A.
  • Genzyme Corporation
  • Gilead Sciences, Inc.
  • Grifols SA
  • ImmunoGen, Inc.
  • Johnson & Johnson
  • Menarini Group
  • Merck & Co., Inc.
  • 田邊三菱製藥
  • Novartis AG
  • Novo Nordisk A/S
  • Sanofi SA
  • 武田藥品工業
  • AbbVie Inc.
  • Amylin Pharmaceuticals, Inc.
  • Biocon Limited
  • CSL Limited
  • Cubist Pharmaceuticals
  • Covance Inc.
  • Esteve Group
  • GE Healthcare
  • MorphoSys AG
  • Onxeo
  • Shanghai Kehua Bio-engineering Co., Ltd
  • Sinovac Biotech Ltd.
  • ThromboGenics NV
  • Transgene S.A.
  • Zambon Company S.p.A.
  • Zeltia SA

用語

圖表

目錄

Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues.

Following the economic recession of 2008-2009, the global biotechnology industry has been growing at a strong rate, despite a slowdown in 2013. However, forecast for the global biotech industry is expected to show strong growth till the year 2019.

Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment.

Aruvian Research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies.

The report begins with an analysis of the global biotechnology industry through industry statistics, industry value analysis and an industry segmentation. We segment the global biotech industry into bioinformatics, genomics, pharmacogenomics and proteomics. We also analyze industry financing and investments. Forecast for the global biotechnology industry is included till 2019. An industry definition precedes this section.

The Global Biotechnology Industry is analyzed through Porter's Five Forces Strategy Analysis. We look at the biotech industry through buyer and supplier power, competitive rivalry in the industry, threat of new entrants and the threat of substitutes.

The blurring differences between biotech and pharma companies is analyzed in our report.

Moving on, we analyze market trends and challenges facing the global biotechnology industry such as the emergence of bioinformatics, biosensor technology, cloning technology, and others. Challenges facing the industry are analyzed such as industry globalization, intellectual property issues, regulatory barriers, lack of investor confidence, financial issues, issues with genetic manipulation, and lack of adequate water, amongst a host of other barriers are all analyzed.

Moving to the analysis of the 23 key biotech markets, we analyze each country through industry statistics, industry value analysis, industry segmentation and forecast till 2019. Countries analyzed include Belgium, Canada, China, France, Germany, Italy, Japan, Netherlands, Spain, United Kingdom and United States. Other markets we analyze briefly include Australia, Brazil, Cuba, Malaysia, New Zealand, Pakistan, Romania, Singapore, South Korea, Sri Lanka, Switzerland and Tanzania.

Major players in the global biotech industry are analyzed through a corporate profile, an analysis of the business segments they operate through, a company strategy wherever available, financial analysis and a SWOT analysis. We analyze a total of 44 companies in the report.

The report Analyzing the Global Biotechnology Industry is ideal for investors, competitors within the industry, as well as companies looking to enter the global biotech market will find this report to be meaningful in understanding the workings of the industry.

Table of Contents

A. Executive Summary

B. Industry Definition

C. Global Biotechnology Industry

  • C.1 Industry Statistics
  • C.2 Industry Value Analysis
  • C.3 Industry Segmentation
    • C.3.1 Bioinformatics
    • C.3.2 Genomics
    • C.3.3 Pharmacogenomics
    • C.3.4 Proteomics
  • C.4 Industry Financing & Investments
  • C.5 Global Biotechnology Industry: Forecast

D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis

  • D.1 Introduction
  • D.2 Bargaining Power of Buyer
  • D.3 Bargaining Power of Suppliers
  • D.4 Competitive Rivalry in the Industry
  • D.5 Threat of New Entrants
  • D.6 Threat of Industry Substitution

E. Blurring Differences between Biotech & Pharma Companies

F. Global Biotechnology Industry: Market Trends & Challenges

  • F.1 Introduction
  • F.2 Bioinformatics
  • F.3 Biosensor Technology
  • F.4 Cell Culture Technology
  • F.5 Cloning Technology
    • F.5.1 Molecular Cloning
    • F.5.2 Cellular Cloning
    • F.5.3 Animal Cloning
  • F.6 DNA Chip Technology
  • F.7 Microarrays
    • F.7.1 DNA Microarrays
    • F.7.2 Protein Microarrays
    • F.7.3 Tissue Microarrays
    • F.7.4 Whole-Cell Microarrays
  • F.8 Monoclonal Antibody Technologies
  • F.9 Nanobiotechnology
  • F.10 Recombinant DNA Technology
  • F.11 Industry Globalization
  • F.12 Challenge to Improve Productivity
  • F.13 Accessibility & Availability of Raw Materials & Energy Sources
  • F.14 Emergence of Personalized Medicine
  • F.15 Challenge Posed by Biosimilars
  • F.16 Cost-efficient Manufacturing
  • F.17 Lack of Investor Confidence
  • F.18 Regulatory Issues
  • F.19 Intellectual Property Challenges & Patents
  • F.20 Financial Barriers
  • F.21 Challenges in Emerging Markets
  • F.22 Issues with Genetic Manipulation
    • F.22.1 Disadvantages of Host Vector Systems
    • F.22.2 Barriers to Establishing and Expressing Foreign DNA
    • F.22.3 Problem of Strain Stability in Industrial Fermentation
    • F.22.4 Mutagenesis and Other Issues
    • F.22.5 Availability of Cell Cultures, Vectors, and DNA Sequences
    • F.22.6 Lack of an Aqueous Environment
  • F.23 Overview of the Challenge
    • F.23.1 Reactor Outputs and the Cost of Water Removal
    • F.23.2 Lack of Water Resources & High Supply of Water Required
    • F.23.3 Challenge with Extensive Use of Biocatalysts
  • F.24 Lack of Public Support

G. Global Biotechnology Industry: Analysis of Key Markets

  • G.1 Belgium
    • G.1.1 Industry Statistics
    • G.1.2 Industry Value Analysis
    • G.1.3 Industry Segmentation
    • G.1.4 Biotechnology Industry in Belgium: Forecast
  • G.2 Canada
    • G.2.1 Industry Statistics
    • G.2.2 Industry Value Analysis
    • G.2.3 Industry Segmentation
    • G.2.4 Biotechnology Industry in Canada: Forecast
  • G.3 China
    • G.3.1 Industry Statistics
    • G.3.2 Industry Value Analysis
    • G.3.3 Industry Segmentation
    • G.3.4 Biotechnology Industry in China: Forecast
  • G.4 France
    • G.4.1 Industry Statistics
    • G.4.2 Industry Value Analysis
    • G.4.3 Industry Segmentation
    • G.4.4 Biotechnology Industry in France: Forecast
  • G.5 Germany
    • G.5.1 Industry Statistics
    • G.5.2 Industry Value Analysis
    • G.5.3 Industry Segmentation
    • G.5.4 Biotechnology Industry in Germany: Forecast
  • G.6 Italy
    • G.6.1 Industry Statistics
    • G.6.2 Industry Value Analysis
    • G.6.3 Industry Segmentation
    • G.6.4 Biotechnology Industry in Italy: Forecast
  • G.7 Japan
    • G.7.1 Industry Statistics
    • G.7.2 Industry Value Analysis
    • G.7.3 Industry Segmentation
    • G.7.4 Biotechnology Industry in Japan: Forecast
  • G.8 Netherlands
    • G.8.1 Industry Statistics
    • G.8.2 Industry Value Analysis
    • G.8.3 Industry Segmentation
    • G.8.4 Biotechnology Industry in Netherlands: Forecast
  • G.9 Spain
    • G.9.1 Industry Statistics
    • G.9.2 Industry Value Analysis
    • G.9.3 Industry Segmentation
    • G.9.4 Biotechnology Industry in Spain: Forecast
  • G.10 United Kingdom
    • G.10.1 Industry Statistics
    • G.10.2 Industry Value Analysis
    • G.10.3 Industry Segmentation
    • G.10.4 Biotechnology Industry in United Kingdom: Forecast
  • G.11 United States
    • G.11.1 Industry Statistics
    • G.11.2 Industry Value Analysis
    • G.11.3 Industry Segmentation
    • G.11.4 Biotechnology Industry in the US: Forecast
  • G.12 Other Markets
    • G.12.1 Australia
    • G.12.2 Brazil
    • G.12.3 Cuba
    • G.12.4 Malaysia
    • G.12.5 New Zealand
    • G.12.6 Pakistan
    • G.12.7 Romania
    • G.12.8 Singapore
    • G.12.9 South Korea
    • G.12.10 Sri Lanka
    • G.12.11 Switzerland
    • G.12.12 Tanzania

H. Global Biotechnology Industry: Major Players

  • H.1 Abbott Laboratories
    • H.1.1 Corporate Profile
    • H.1.2 Business Segment Analysis
    • H.1.3 Company Strategy
    • H.1.4 Financial Analysis
    • H.1.5 SWOT Analysis
  • H.2 Acorda Therapeutics Inc.
    • H.2.1 Corporate Profile
    • H.2.2 Business Segment Analysis
    • H.2.3 Financial Analysis
    • H.2.4 SWOT Analysis
  • H.3 Actelion Ltd
    • H.3.1 Corporate Profile
    • H.3.2 Business Segment Analysis
    • H.3.3 Financial Analysis
    • H.3.4 SWOT Analysis
  • H.4 Amgen, Inc.
    • H.4.1 Corporate Profile
    • H.4.2 Business Segment Analysis
    • H.4.3 Company Strategy
    • H.4.4 Financial Analysis
    • H.4.5 SWOT Analysis
  • H.5 Astellas Pharma Inc.
    • H.5.1 Corporate Profile
    • H.5.2 Business Segment Analysis
    • H.5.3 Financial Analysis
    • H.5.4 SWOT Analysis
  • H.6 AstraZeneca Plc
    • H.6.1 Corporate Profile
    • H.6.2 Business Segment Analysis
    • H.6.3 Company Strategy
    • H.6.4 Financial Analysis
    • H.6.5 SWOT Analysis
  • H.7 Baxter International Inc.
    • H.7.1 Corporate Profile
    • H.7.2 Business Segment Analysis
    • H.7.3 Company Strategy
    • H.7.4 Financial Analysis
    • H.7.5 SWOT Analysis
  • H.8 Biogen Inc.
    • H.8.1 Corporate Profile
    • H.8.2 Business Segment Analysis
    • H.8.3 Company Strategy
    • H.8.4 Financial Analysis
    • H.8.5 SWOT Analysis
  • H.9 bioMerieux SA
    • H.9.1 Corporate Profile
    • H.9.2 Business Segment Analysis
    • H.9.3 Financial Analysis
    • H.9.4 SWOT Analysis
  • H.10 Boehringer Ingelheim GmbH
    • H.10.1 Corporate Profile
    • H.10.2 Business Segment Analysis
    • H.10.3 Financial Analysis
    • H.10.4 SWOT Analysis
  • H.11 Bristol-Myers Squibb Company
    • H.11.1 Corporate Profile
    • H.11.2 Business Segment Analysis
    • H.11.3 Company Strategy
    • H.11.4 Financial Analysis
    • H.11.5 SWOT Analysis
  • H.12 Celgene Corporation
    • H.12.1 Corporate Profile
    • H.12.2 Business Segment Analysis
    • H.12.3 Company Strategy
    • H.12.4 Financial Analysis
    • H.12.5 SWOT Analysis
  • H.13 Crucell N.V.
    • H.13.1 Corporate Profile
    • H.13.2 Business Segment Analysis
    • H.13.3 Financial Analysis
    • H.13.4 SWOT Analysis
  • H.14 Daiichi Sankyo Co., Ltd.
    • H.14.1 Corporate Profile
    • H.14.2 Business Segment Analysis
    • H.14.3 Financial Analysis
    • H.14.4 SWOT Analysis
  • H.15 F. Hoffmann-La Roche AG
    • H.15.1 Corporate Profile
    • H.15.2 Business Segment Analysis
    • H.15.3 Financial Analysis
    • H.15.4 SWOT Analysis
  • H.16 Gentium S.p.A.
    • H.16.1 Corporate Profile
    • H.16.2 Business Segment Analysis
    • H.16.3 Financial Analysis
    • H.16.4 SWOT Analysis
  • H.17 Genzyme Corporation
    • H.17.1 Corporate Profile
    • H.17.2 Business Segment Analysis
    • H.17.3 Financial Analysis
    • H.17.4 SWOT Analysis
  • H.18 Gilead Sciences, Inc.
    • H.18.1 Corporate Profile
    • H.18.2 Business Segment Analysis
    • H.18.3 Company Strategy
    • H.18.4 Financial Analysis
    • H.18.5 SWOT Analysis
  • H.19 Grifols SA
    • H.19.1 Corporate Profile
    • H.19.2 Business Segment Analysis
    • H.19.3 Financial Analysis
    • H.19.4 SWOT Analysis
  • H.20 ImmunoGen, Inc.
    • H.20.1 Corporate Profile
    • H.20.2 Business Segment Analysis
    • H.20.3 Financial Analysis
    • H.20.4 SWOT Analysis
  • H.21 Johnson & Johnson
    • H.21.1 Corporate Profile
    • H.21.2 Business Segment Analysis
    • H.21.3 Company Strategy
    • H.21.4 Financial Analysis
    • H.21.5 SWOT Analysis
  • H.22 Menarini Group
    • H.22.1 Corporate Profile
    • H.22.2 Business Segment Analysis
    • H.22.3 Financial Analysis
    • H.22.4 SWOT Analysis
  • H.23 Merck & Co., Inc.
    • H.23.1 Corporate Profile
    • H.23.2 Business Segment Analysis
    • H.23.3 Company Strategy
    • H.23.4 Financial Analysis
    • H.23.5 SWOT Analysis
  • H.24 Mitsubishi Tanabe Pharma Corporation
    • H.24.1 Corporate Profile
    • H.24.2 Business Segment Analysis
    • H.24.3 Financial Analysis
    • H.24.4 SWOT Analysis
  • H.25 Novartis AG
    • H.25.1 Corporate Profile
    • H.25.2 Business Segment Analysis
    • H.25.3 Company Strategy
    • H.25.4 Financial Analysis
    • H.25.5 SWOT Analysis
  • H.26 Novo Nordisk A/S
    • H.26.1 Corporate Profile
    • H.26.2 Business Segment Analysis
    • H.26.3 Company Strategy
    • H.26.4 Financial Analysis
    • H.26.5 SWOT Analysis
  • H.27 Sanofi SA
    • H.27.1 Corporate Profile
    • H.27.2 Business Segment Analysis
    • H.27.3 Company Strategy
    • H.27.4 Financial Analysis
    • H.27.5 SWOT Analysis
  • H.28 Takeda Pharmaceutical Co Ltd
    • H.28.1 Corporate Profile
    • H.28.2 Business Segment Analysis
    • H.28.3 Financial Analysis
    • H.28.4 SWOT Analysis
  • H.29 AbbVie Inc.
  • H.30 Amylin Pharmaceuticals, Inc.
  • H.31 Biocon Limited
  • H.32 CSL Limited
  • H.33 Cubist Pharmaceuticals
  • H.34 Covance Inc.
  • H.35 Esteve Group
  • H.36 GE Healthcare
  • H.37 MorphoSys AG
  • H.38 Onxeo
  • H.39 Shanghai Kehua Bio-engineering Co., Ltd
  • H.40 Sinovac Biotech Ltd.
  • H.41 ThromboGenics NV
  • H.42 Transgene S.A.
  • H.43 Zambon Company S.p.A.
  • H.44 Zeltia SA

I. Glossary of Terms

List of Figures

  • Figure 1: Growth of the Global Biotechnology Industry by Value (in USD Billion), 2010-2014
  • Figure 2: Global Biotechnology Industry Segmentation (%), 2014
  • Figure 3: Global Biotechnology Industry Share by Regions (%), 2014
  • Figure 4: Forecast for the Global Biotechnology Industry (in USD Billion), 2014-2019
  • Figure 5: Porter's Five Forces Analysis of the Global Biotechnology Industry
  • Figure 6: Buyer Power in the Global Biotechnology Industry
  • Figure 7: Supplier Power in the Global Biotechnology Industry
  • Figure 8: Threat of New Entrants in the Global Biotechnology Industry
  • Figure 9: Growth of the Biotechnology Industry in Belgium by Value (in USD Billion), 2010-2014
  • Figure 10: Belgium Biotechnology Industry Segmentation (%), 2014
  • Figure 11: Share of Belgium in the European Biotechnology Industry (%), 2014
  • Figure 12: Forecast for the Biotechnology Industry in Belgium (in USD Billion), 2014-2019
  • Figure 13: Growth of the Biotechnology Industry in Canada by Value (in USD Billion), 2010-2014
  • Figure 14: Canada Biotechnology Industry Segmentation (in USD Billion & %), 2014
  • Figure 15: Share of Canada in the Americas Biotechnology Industry (%), 2014
  • Figure 16: Forecast for the Biotechnology Industry in Canada (in USD Billion), 2014-2019
  • Figure 17: Growth of the Biotechnology Industry in China by Value (in USD Billion), 2010-2014
  • Figure 18: China Biotechnology Industry Segmentation (%), 2014
  • Figure 19: Share of China in the Asia Pacific Biotechnology Industry (%), 2014
  • Figure 20: Forecast for the Biotechnology Industry in China (in USD Billion), 2014-2019
  • Figure 21: Growth of the Biotechnology Industry in France by Value (in USD Billion), 2010-2014
  • Figure 22: France Biotechnology Industry Segmentation (%), 2014
  • Figure 23: Share of France in the European Biotechnology Industry (in USD Billion & %), 2014
  • Figure 24: Forecast for the Biotechnology Industry in France (in USD Billion), 2014-2019
  • Figure 25: Growth of the Biotechnology Industry in Germany by Value (in USD Billion), 2010-2014
  • Figure 26: Germany Biotechnology Industry Segmentation (%), 2014
  • Figure 27: Share of Germany in the European Biotechnology Industry (%), 2014
  • Figure 28: Forecast for the Biotechnology Industry in Germany (in USD Billion), 2014-2019
  • Figure 29: Growth of the Biotechnology Industry in Italy by Value (in USD Billion), 2010-2014
  • Figure 30: Italy Biotechnology Industry Segmentation (%), 2014
  • Figure 31: Share of Italy in the European Biotechnology Industry (%), 2014
  • Figure 32: Forecast for the Biotechnology Industry in Italy (in USD Billion), 2014-2019
  • Figure 33: Growth of the Biotechnology Industry in Japan by Value (in USD Billion), 2010-2014
  • Figure 34: Japan Biotechnology Industry Segmentation (%), 2014
  • Figure 35: Share of Japan in the Asia Pacific Biotechnology Industry (%), 2014
  • Figure 36: Forecast for the Biotechnology Industry in Japan (in USD Billion), 2014-2019
  • Figure 37: Growth of the Biotechnology Industry in the Netherlands by Value (in USD Million), 2010-2014
  • Figure 38: Netherlands Biotechnology Industry Segmentation (%), 2014
  • Figure 39: Share of Netherlands in the European Biotechnology Industry (%), 2014
  • Figure 40: Forecast for the Biotechnology Industry in Netherlands (in USD Million), 2014-2019
  • Figure 41: Growth of the Biotechnology Industry in Spain by Value (in USD Billion), 2010-2014
  • Figure 42: Spain Biotechnology Industry Segmentation (%), 2014
  • Figure 43: Share of Spain in the European Biotechnology Industry (%), 2014
  • Figure 44: Forecast for the Biotechnology Industry in Spain (in USD Billion), 2014-2019
  • Figure 45: Growth of the Biotechnology Industry in the UK by Value (in USD Billion), 2010-2014
  • Figure 46: UK Biotechnology Industry Segmentation (%), 2014
  • Figure 47: Share of the UK in the European Biotechnology Industry (%), 2014
  • Figure 48: Forecast for the Biotechnology Industry in the UK (in USD Billion), 2014-2019
  • Figure 49: Growth of the Biotechnology Industry in the US by Value (in USD Billion), 2010-2014
  • Figure 50: United States Biotechnology Industry Segmentation (%), 2014
  • Figure 51: Share of the US in the Global Biotechnology Industry (%), 2014
  • Figure 52: Forecast for the Biotechnology Industry in the US (in USD Billion), 2014-2019
  • Figure 53: Actelion Ltd. Revenues & Profitability (in USD Million), 2009-2013
  • Figure 54: Amgen Inc. Revenues & Profitability (in USD Million), 2009-2013
  • Figure 55: Astellas Pharma Inc. Revenues & Profitability (in USD Million), 2009-2013
  • Figure 56: AstraZeneca Plc Revenues & Profitability (in USD Million), 2009-2013
  • Figure 57: Baxter International Revenues & Profitability (in USD Million), 2009-2013
  • Figure 58: Biogen Revenues & Profitability (in USD Million), 2009-2013
  • Figure 59: bioMerieux SA Revenues & Profitability (in USD Million), 2009-2013
  • Figure 60: Boehringer Ingelheim GmbH Revenues & Profitability (in USD Million), 2009-2013
  • Figure 61: Daiichi Sankyo Co., Ltd. Revenues & Profitability (in USD Million), 2010-2014
  • Figure 62: F. Hoffmann-La Roche AG Revenues & Profitability (in USD Million), 2010-2014
  • Figure 63: Grifols SA Revenues & Profitability (in USD Million), 2009-2013
  • Figure 64: Merck & Co., Inc. Revenues & Profitability (in USD Million), 2009-2013
  • Figure 65: Mitsubishi Tanabe Pharma Corporation Revenues & Profitability (in USD Million), 2010-2014
  • Figure 66: Novartis AG Revenues & Profitability (in USD Million), 2009-2013
  • Figure 67: Novo Nordisk A/S Revenues & Profitability (in USD Million), 2010-2014
  • Figure 68: Sanofi SA Revenues & Profitability (in USD Million), 2009-2013
  • Figure 69: Takeda Pharmaceutical Company Limited Revenues & Profitability (in USD Million), 2010-2014
  • Figure 70: Covance Inc. Revenues & Profitability (in USD Million), 2009-2013
  • Figure 71: MorphoSys AG Revenues & Profitability (in USD Million), 2009-2013
  • Figure 72: Onxeo SA Revenues & Profitability (in USD Million), 2009-2013
  • Figure 73: Shanghai Kehua Bio-engineering Co., Ltd Revenues & Profitability (in USD Million), 2009-2013
  • Figure 74: Sinovac Biotech Ltd. Revenues & Profitability (in USD Million), 2009-2013
  • Figure 75: ThromboGenics NV Revenues & Profitability (in USD Million), 2009-2013
  • Figure 76: Transgene S.A. Revenues & Profitability (in USD Million), 2009-2013
  • Figure 77: Zeltia, S.A. Revenues & Profitability (in USD Million), 2009-2013

List of Tables

  • Table 1: Growth of the Global Biotechnology Industry by Value (in USD Billion), 2010-2014
  • Table 2: Global Biotechnology Industry Segmentation (in USD Billion & %), 2014
  • Table 3: Global Biotechnology Industry Share by Regions (in USD Billion & %), 2014
  • Table 4: Forecast for the Global Biotechnology Industry (in USD Billion), 2014-2019
  • Table 5: Growth of the Biotechnology Industry in Belgium by Value (in USD Billion), 2010-2014
  • Table 6: Belgium Biotechnology Industry Segmentation (in USD Billion & %), 2014
  • Table 7: Share of Belgium in the European Biotechnology Industry (in USD Billion & %), 2014
  • Table 8: Forecast for the Biotechnology Industry in Belgium (in USD Billion), 2014-2019
  • Table 9: Growth of the Biotechnology Industry in Canada by Value (in USD Billion), 2010-2014
  • Table 10: Canada Biotechnology Industry Segmentation (in USD Billion & %), 2014
  • Table 11: Share of Canada in the Americas Biotechnology Industry (in USD Billion & %), 2014
  • Table 12: Forecast for the Biotechnology Industry in Canada (in USD Billion), 2014-2019
  • Table 13: Growth of the Biotechnology Industry in China by Value (in USD Billion), 2010-2014
  • Table 14: China Biotechnology Industry Segmentation (in USD Billion & %), 2014
  • Table 15: Share of China in the Asia Pacific Biotechnology Industry (in USD Billion & %), 2014
  • Table 16: Forecast for the Biotechnology Industry in China (in USD Billion), 2014-2019
  • Table 17: Growth of the Biotechnology Industry in France by Value (in USD Billion), 2010-2014
  • Table 18: France Biotechnology Industry Segmentation (in USD Billion & %), 2014
  • Table 19: Share of France in the European Biotechnology Industry (in USD Billion & %), 2014
  • Table 20: Forecast for the Biotechnology Industry in France (in USD Billion), 2014-2019
  • Table 21: Growth of the Biotechnology Industry in Germany by Value (in USD Billion), 2010-2014
  • Table 22: Germany Biotechnology Industry Segmentation (in USD Billion & %), 2014
  • Table 23: Share of Germany in the European Biotechnology Industry (in USD Billion & %), 2014
  • Table 24: Forecast for the Biotechnology Industry in Germany (in USD Billion), 2014-2019
  • Table 25: Growth of the Biotechnology Industry in Italy by Value (in USD Billion), 2010-2014
  • Table 26: Italy Biotechnology Industry Segmentation (in USD Billion & %), 2014
  • Table 27: Share of Italy in the European Biotechnology Industry (in USD Billion & %), 2014
  • Table 28: Forecast for the Biotechnology Industry in Italy (in USD Billion), 2014-2019
  • Table 29: Growth of the Biotechnology Industry in Japan by Value (in USD Billion), 2010-2014
  • Table 30: Japan Biotechnology Industry Segmentation (in USD Billion & %), 2014
  • Table 31: Share of Japan in the Asia Pacific Biotechnology Industry (in USD Billion & %), 2014
  • Table 32: Forecast for the Biotechnology Industry in Japan (in USD Billion), 2014-2019
  • Table 33: Growth of the Biotechnology Industry in the Netherlands by Value (in USD Million), 2010-2014
  • Table 34: Netherlands Biotechnology Industry Segmentation (in USD Million & %), 2014
  • Table 35: Share of Netherlands in the European Biotechnology Industry (in USD Million & %), 2014
  • Table 36: Forecast for the Biotechnology Industry in Netherlands (in USD Million), 2014-2019
  • Table 37: Growth of the Biotechnology Industry in Spain by Value (in USD Billion), 2010-2014
  • Table 38: Spain Biotechnology Industry Segmentation (in USD Billion & %), 2014
  • Table 39: Share of Spain in the European Biotechnology Industry (in USD Billion & %), 2014
  • Table 40: Forecast for the Biotechnology Industry in Spain (in USD Billion), 2014-2019
  • Table 41: Growth of the Biotechnology Industry in the UK by Value (in USD Billion), 2010-2014
  • Table 42: UK Biotechnology Industry Segmentation (in USD Billion & %), 2014
  • Table 43: Share of the UK in the European Biotechnology Industry (in USD Billion & %), 2014
  • Table 44: Forecast for the Biotechnology Industry in the UK (in USD Billion), 2014-2019
  • Table 45: Growth of the Biotechnology Industry in the US by Value (in USD Billion), 2010-2014
  • Table 46: United States Biotechnology Industry Segmentation (in USD Billion & %), 2014
  • Table 47: Share of the US in the Global Biotechnology Industry (in USD Billion & %), 2014
  • Table 48: Forecast for the Biotechnology Industry in the US (in USD Billion), 2014-2019
  • Table 49: Malaysian Biotechnology Sector Overview, 2014
  • Table 50: Financial Performance of Abbott Laboratories (in USD Million), Quarter Ending June 30, 2015
  • Table 51: Financial Analysis of Actelion Ltd. (in USD Million), 2009-2013
  • Table 52: Financial Performance of Amgen Inc. (in USD Million), 2009-2013
  • Table 53: Financial Performance of Astellas Pharma Inc. (in USD Million), 2009-2013
  • Table 54: Financial Performance of AstraZeneca Plc (in USD Million), 2009-2013
  • Table 55: Financial Performance of Baxter International (in USD Million), 2009-2013
  • Table 56: Financial Performance of Biogen (in USD Million), 2009-2013
  • Table 57: Financial Performance of bioMerieux SA (in USD Million), 2009-2013
  • Table 58: Financial Performance of Boehringer Ingelheim GmbH (in USD Million), 2009-2013
  • Table 59: Financial Performance of Bristol-Myers Squibb Company (in USD Million), for quarter ending June 30, 2015
  • Table 60: Financial Performance of Celgene Corporation (in USD Million), for quarter ending June 30, 2015
  • Table 61: Financial Performance of Daiichi Sankyo Co., Ltd. (in USD Million), 2010-2014
  • Table 62: Financial Performance of F. Hoffmann-La Roche AG (in USD Million), 2010-2014
  • Table 63: Annual Profit & Loss Statement of Gentium (in USD Million), 2013-2011
  • Table 64: Financial Performance of Grifols SA (in USD Million), 2009-2013
  • Table 65: Financial Performance of Johnson & Johnson (in USD Million), for the quarter ending June 28, 2015
  • Table 66: Financial Performance of Merck & Co., Inc. (in USD Million), 2009-2013
  • Table 67: Financial Performance of Mitsubishi Tanabe Pharma Corporation (in USD Million), 2010-2014
  • Table 68: Financial Analysis of Novartis AG (in USD Million), 2009-2013
  • Table 69: Financial Performance of Novo Nordisk A/S (in USD Million), 2010-2014
  • Table 70: Financial Performance of Sanofi SA (in USD Million), 2009-2013
  • Table 71: Financial Performance of Takeda Pharmaceutical Company Limited (in USD Million), 2010-2014
  • Table 72: Financial Performance of Covance Inc. (in USD Million), 2009-2013
  • Table 73: Financial Performance of MorphoSys AG (in USD Million), 2009-2013
  • Table 74: Financial Performance of Onxeo SA (in USD Million), 2009-2013
  • Table 75: Financial Performance of Shanghai Kehua Bio-engineering Co., Ltd (in USD Million), 2009-2013
  • Table 76: Financial Performance of Sinovac Biotech Ltd. (in USD Million), 2009-2013
  • Table 77: Financial Performance of ThromboGenics NV (in USD Million), 2009-2013
  • Table 78: Financial Performance of Transgene S.A. (in USD Million), 2009-2013
  • Table 79: Financial Performance of Zeltia, S.A. (in USD Million), 2009-2013
Back to Top